Adverse Events, Comorbidities, and HIV

Dec. 5, 2019: The value of pre-treatment drug resistance testing; resistance rates among viremic Americans; persistent pneumonia incidence among people with HIV; mixed HIV prevention results for the U.S. National HIV Strategy.

Montreal scientists found that 88% of cannabis users had an undetectable viral load. This suggests that a very large majority of cannabis users did not have problems adhering to antiretroviral therapy.

Will a given development in HIV make a difference in the clinic? Will it change practice? Is this something I should know if I take care of people living with HIV? The answer to each of these must be yes for the story to make the list.

In a busy year buzzing with the flight of potentially revolutionary new HIV medications, evidence of large weight increases accompanying dolutegravir and bictegravir has been a bombshell.

A lot of pregnancies in Botswana were anxiously followed after results from the Tsepamo study were revealed in late 2018. Updated data provide a medium-sized sigh of relief.

An international team of experts conducted a thoughtful review of existing research regarding the use of doxycycline for STI prevention. Do the risks of its use outweigh the benefits?

Nov. 20, 2019: Adherence required to maintain suppression; the accuracy of Framingham scores in assessing cardiovascular risk; long-term success rates for kidney transplants; integration of hypertension services with HIV care.

Taking more than five medications could be a problem. And many people with HIV are at risk of being on medication overload.

While there is not yet an app for helping patients to manage their fatigue, nurses can help patients get out of the house by finding a physical activity they enjoy.

Trauma-informed care should be implemented in all care settings, a study presented at the Association of Nurses in AIDS Care conference finds.